[go: up one dir, main page]

AR029958A1 - Uso de fosfato de estramustina en el tratamiento de metastasis osea y en el tratamiento de metastasis osea en pacientes con cancer de prostata - Google Patents

Uso de fosfato de estramustina en el tratamiento de metastasis osea y en el tratamiento de metastasis osea en pacientes con cancer de prostata

Info

Publication number
AR029958A1
AR029958A1 ARP010103500A ARP010103500A AR029958A1 AR 029958 A1 AR029958 A1 AR 029958A1 AR P010103500 A ARP010103500 A AR P010103500A AR P010103500 A ARP010103500 A AR P010103500A AR 029958 A1 AR029958 A1 AR 029958A1
Authority
AR
Argentina
Prior art keywords
osea
metastasis
treatment
stramustin
patients
Prior art date
Application number
ARP010103500A
Other languages
English (en)
Inventor
Asp Beryl
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR029958A1 publication Critical patent/AR029958A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se observa que el fosfato de estramustina actua como inhibidor de reabsorcion osea y por lo tanto puede utilizarse para tratar, prevenir o aliviar los síntomas de metástasis osea que surgen debido a dicha reabsorcion osea.
ARP010103500A 2000-07-25 2001-07-23 Uso de fosfato de estramustina en el tratamiento de metastasis osea y en el tratamiento de metastasis osea en pacientes con cancer de prostata AR029958A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/625,540 US6436913B1 (en) 2000-07-25 2000-07-25 Use of estramustine phosphate in the treatment of bone metastasis

Publications (1)

Publication Number Publication Date
AR029958A1 true AR029958A1 (es) 2003-07-23

Family

ID=24506563

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103500A AR029958A1 (es) 2000-07-25 2001-07-23 Uso de fosfato de estramustina en el tratamiento de metastasis osea y en el tratamiento de metastasis osea en pacientes con cancer de prostata

Country Status (13)

Country Link
US (1) US6436913B1 (es)
EP (1) EP1328264A4 (es)
JP (1) JP2004504346A (es)
KR (1) KR20030019612A (es)
CN (1) CN1446086A (es)
AR (1) AR029958A1 (es)
AU (1) AU2001277115A1 (es)
BR (1) BR0112721A (es)
CA (1) CA2412392A1 (es)
MX (1) MXPA03000313A (es)
PE (1) PE20020301A1 (es)
WO (1) WO2002007719A1 (es)
ZA (1) ZA200210285B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
IT1318689B1 (it) * 2000-09-12 2003-08-27 Pharmacia & Upjohn Spa Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla
US20040014729A1 (en) * 2001-07-23 2004-01-22 Beryl Asp Use of estramustine phosphate in the treatment of bone metastasis
CA2530279A1 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
JP2005055881A (ja) * 2003-07-22 2005-03-03 Fuji Photo Film Co Ltd 描画方法および描画装置
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
WO2011066379A2 (en) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US5597830A (en) 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
BR9906425A (pt) * 1998-03-27 2000-07-11 Upjohn Co Métodos para potencializar fosfato de estramustina intravenoso
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death

Also Published As

Publication number Publication date
CA2412392A1 (en) 2002-01-31
CN1446086A (zh) 2003-10-01
WO2002007719A1 (en) 2002-01-31
AU2001277115A1 (en) 2002-02-05
ZA200210285B (en) 2003-12-19
EP1328264A1 (en) 2003-07-23
US6436913B1 (en) 2002-08-20
JP2004504346A (ja) 2004-02-12
MXPA03000313A (es) 2003-06-06
KR20030019612A (ko) 2003-03-06
EP1328264A4 (en) 2004-01-28
PE20020301A1 (es) 2002-04-07
BR0112721A (pt) 2003-06-24

Similar Documents

Publication Publication Date Title
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
DE60106954D1 (de) Resorcin-derivate
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
AU307707S (en) Foot guard
MEP64008A (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
AR029958A1 (es) Uso de fosfato de estramustina en el tratamiento de metastasis osea y en el tratamiento de metastasis osea en pacientes con cancer de prostata
ECSP034866A (es) Combinaciones antineoplásticas
DE60323645D1 (de) Duschvorrichtung mit bräunungsvorrichtung
SV2001000212A (es) Una combinacion de agentes antineoplasticos que comprenden acetildinalina y paclitaxel y/o carboplatina y juego que la comprende
ECSP034790A (es) Combinaciones antineoplásticas tales como rapamicin junto con gemcitabina o fluorouracil
PT1214061E (pt) Nova utilizacao de docetaxel para o tratamento do carcinoma hepatocelular
CL2004000558A1 (es) Metodo para tratar los materiales de construccion, donde se introduce un complejo de borato-cobre soluble en agua, y dichos materiales de construccion tratados.
BR0012675A (pt) Uso de inibidores de il-18
FR2879598B1 (fr) Inhibiteurs de phosphatases cdc25
AR013760A1 (es) Oligonucleotidos antisentido contra tenascina para el tratamiento de vitiligo.
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
SE9800139D0 (sv) New use
DK1150682T3 (da) Ubichinon Qn til behandling af migrænesmerter
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
CO5280204A1 (es) Uso de glutamina para la prevencion de la diarrea de inicio tardio inducida por irinotecan
UY27414A1 (es) Sulfamatos de 2-alcoxiestradiol de acción antitumoral
DOP2003000674A (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoolasicas
ECSP024236A (es) Derivados quimicos y su aplicación como agente antitelomerasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal